Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Zacks Investment Research Inc.
$12.00
Provider: Zacks Investment Research Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Evoke Pharma Inc Announces Closing of Initial Public Offering of 2,100,000 Shares of Common Stock


Monday, 30 Sep 2013 04:15pm EDT 

Evoke Pharma Inc announced the closing of its previously announced initial public offering of common stock. The Company sold a total of 2,100,000 shares of its common stock, at an initial public offering price of $12.00 per share. The gross proceeds to Evoke Pharma from the initial public offering were $25,200,000, before underwriting discounts and commissions and estimated offering expenses. Evoke Pharma has granted the representative of the underwriters a 30 day option to purchase up to 315,000 additional shares of common stock from the Company to cover over-allotments, if any. Aegis Capital Corp. acted as sole book-running manager for the offering. Cantor Fitzgerald & Co. and Feltl and Company, Inc. acted as co-managers for the offering. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 24, 2013. 

Company Quote

5.49
-0.06 -1.08%
30 Sep 2014